News & Events about Verve Therapeutics Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK, Jan. 4, 2023...
NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verve Therapeutics, Inc. (Verve or the Company) (NASDAQ: VERV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV PR Newswire NEW YORK, Dec. 26, 2022 NEW YORK, Dec. 26, 2022...
NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verve Therapeutics, Inc. (Verve or the Company) (NASDAQ: VERV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation...
Shares of Verve Therapeutics, Inc. (NASDAQ:VERV Get Rating) have been given an average rating of Moderate Buy by the seven brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and three have...